SEARCH:   Advanced

Blood, 15 January 2008, Vol. 111, No. 2, pp. 878-884. Prepublished online as a Blood First Edition Paper on October 17, 2007; DOI 10.1182/blood-2007-05-087833. This Article Abstract Full Text (PDF) All Versions of this Article: blood-2007-05-087833v1 111/2/878    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cross, A. Articles by Edwards, S. W. Search for Related Content PubMed PubMed Citation Articles by Cross, A. Articles by Edwards, S. W. Related Collections Phagocytes Apoptosis Gene Expression Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  PHAGOCYTES The dual effects of TNF on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1 Andrew Cross1, Robert J. Moots2, and Steven W. Edwards1 1 School of Biological Sciences, Biosciences Building, and 2 School of Clinical Sciences, University of Liverpool, Liverpool, United Kingdom    Abstract Top Abstract Introduction Methods Results Discussion Authorship References   Neutrophils have a very short half-life in the circulation, undergoing rapid death by apoptosis, but a number of agents can either delay or accelerate the rate at which these cells undergo death. TNF can exert opposing, concentration-dependent effects on neutrophils to either accelerate their apoptosis or enhance their survival. We show that TNF greatly increases the rate of turnover of Mcl-1, an antiapoptotic protein that plays a key role in neutrophil survival. In contrast to Mcl-1 turnover in control- or granulocyte-macrophage colony-stimulating factor (GM-CSF)–treated neutrophils that occurs via the proteasome, TNF-accelerated Mcl-1 turnover occurs via activation of caspases. Mcl-1–depleted cells thus have accelerated rates of apoptosis. While TNF had no effect on MCL-1 transcription, it induced expression of another antiapoptotic molecule, BFL-1. Low concentrations of TNF ( 1 ng/mL) stimulated BFL-1 expression, whereas higher concentrations ( 10 ng/mL) triggered caspase-dependent acceleration of Mcl-1 turnover. These opposing effects on 2 separate antiapoptotic systems of neutrophils explain the divergent effects of TNF on neutrophil apoptosis and have important implications for understanding how TNF may affect immune function in inflammatory diseases.    Introduction Top Abstract Introduction Methods Results Discussion Authorship References   Apoptosis of neutrophils, followed by their safe removal via phagocytosis, is essential for the resolution of inflammation and prevention of tissue damage. Circulating neutrophils have a very short half-life of only a few hours in the circulation, but signals such as adhesion, transmigration, hypoxia, and cytokines can all delay their apoptosis and extend their lifespan, thereby enhancing their ability to function during inflammatory challenge.1 Once their function is complete, then death signals (eg, death receptor engagement or cytokine depletion) trigger apoptosis and phagocytic removal of apoptotic neutrophils by macrophages or endo/epithelial cells. Many inflammatory conditions are considered to result from defective apoptosis of immune cells, and so understanding the molecular processes that either control neutrophil death or survival could have therapeutic potential.2 The antiapoptotic protein, Mcl-1, plays a major role in controlling the rate at which neutrophils undergo apoptosis.3,4 Cellular levels of Mcl-1 are regulated by its rate of transcription, but also by the rate of turnover of the protein.5 Mcl-1 has a very short half-life in cells and tissues of approximately 3 hours,5,6 being degraded by the proteasome. Agents that delay apoptosis in cells such as cytokines, can stimulate small, but significant increases in MCL-1 mRNA,5 but their major effects are often to enhance cellular protein levels by delaying its rate of turnover.7,8 This enhanced Mcl-1 stability occurs via signaling pathways involving Raf, PI3K, GSK, and ERK.7–9 Alternatively, some agents can significantly increase the rate of Mcl-1 turnover and thereby enhance neutrophil apoptosis. For example, sodium salicylate treatment decreases the half-life of Mcl-1 to approximately 1.5 hours, and under these conditions, turnover occurs via caspase cleavage rather than proteasomal degradation.10 There is much interest in understanding the role of TNF in the regulation of inflammation, in view of the fact that remarkable benefits of anti-TNF therapy are often observed in diseases such as rheumatoid arthritis11 and inflammatory bowel disease.12 TNF is reported to regulate neutrophil apoptosis,13–16 but differential effects are seen in that it can accelerate death in a subpopulation of cells but delay apoptosis in the subpopulation that escapes this initial death signal.17 It has been proposed that these differential effects are concentration dependent, with high concentrations acting as a death signal, but lower concentrations stimulating apoptosis delay.18 In this report, we show that these opposing, concentration-dependent effects of TNF on neutrophil apoptosis are due to differential effects on neutrophil survival mechanisms. The rapid cell death occurs via accelerated, caspase-dependent Mcl-1 degradation, while survival may be mediated by enhanced expression of another antiapoptotic molecule, Bfl-1.    Methods Top Abstract Introduction Methods Results Discussion Authorship References   This study was approved by the NHS COREC [National Health Service Central Office for Research Ethics Committee] and the University of Liverpool Committee on Research Ethics. Materials Polymorphprep was from Axis-Shield (Oslo, Norway); RPMI 1640 medium and TRIzol reagent were from GibcoBRL (Paisley, United Kingdom). FCS, luminol, cycloheximide, PMA, and peroxidase-linked goat antimouse antibodies were from Sigma (Poole, United Kingdom). Cytokines used were granulocyte-macrophage colony-stimulating factor (GM-CSF; Glaxo, Greenford, United Kingdom) and TNF (Calbiochem, Nottingham, United Kingdom). Caspase inhibitor Z-VAD-FMK and proteasome inhibitor MG-132 were from Calbiochem. FITC-conjugated CD15 and CD16 antibodies and Mcl-1 and Bax antibodies were from BD Biosciences (Oxford, United Kingdom); GAPDH antibody was from Abcam (Cambridge, United Kingdom); caspase antibodies were from Cell Signaling Technology (Boston, MA); while peroxidase-linked donkey antirabbit antibodies, enhanced chemiluminescence (ECL) detection kit, and Amplify were from Amersham (Amersham, United Kingdom). The Dual Luciferase Assay System, pGL-3 Basic reporter vector, pRL-SV40 (Rluc), AMW reverse transcriptase, and dNTP mix were from Promega (Southampton, United Kingdom). Rapid Romanowsky stain was from HD Supplies (Ayelsbury, United Kingdom). MitoTracker red was from Invitrogen (Paisley, United Kingdom). RNeasy mini kit and Quantitect SYBR Green polymerase chain reaction (PCR) kit were from Qiagen (Crawley, United Kingdom). Oligonucleotides were from MWG-Biotech AG (Ebersberg, Germany). Atlas nylon arrays were from Clontech (Mountain View, CA). Cell isolation and culture Neutrophils were isolated using Polymorphprep (as described in the manufacturer's instructions).19–21 Contaminating erythrocytes were removed by hypotonic lysis. Neutrophils were routinely examined for purity and viability using trypan blue exclusion, which were more than 97% and more than 98%, respectively, immediately after isolation. Purity was confirmed using morphologic analysis of cytospins, and CD15 and/or CD16 expression.22,23 Purified neutrophils were resuspended in RPMI 1640 with 25 mM HEPES, supplemented with 10% FCS and 1 mM L-glutamine, at 5 x 106 cells/mL and cultured at 37°C in a humidified incubator. Cytokines and inhibitors were added as indicated. HeLa cells were cultured and maintained in MEM supplemented with 10% FCS and nonessential amino acids and incubated at 37°C in a humidified incubator with 5% CO2. Measurements of apoptosis Following culture, a 20-µL aliquot of neutrophil suspension (105 cells) was made up to 200 µL with RPMI 1640, and cells were cytocentrifuged using a Shandon Cytospin3 (Runcorn, Cheshire, United Kingdom). Romanowsky staining of cytospins allowed apoptosis to be scored by morphology. This method correlates well with other markers of apoptosis.24 In addition, apoptosis was determined by measurement of FITC–annexin V binding and flow cytometry as described previously.8 Mitochondrial staining Neutrophils (106) were incubated in 2 mL supplemented media in 35-mm glass-bottomed Iwaki culture dishes (Barlow Scientific, Stone, United Kingdom), and 25 nM MitoTracker red (CM-H2XRos) was used to monitor the mitochondrial membrane potential. Cells were incubated on a gas- and temperature-controlled microscope stage, and fluorescence was visualized using a LSM510 confocal microscope (Carl Zeiss, New York, NY) at 1024 x 1024 pixel resolution through a 63x Plan Apochromat (NA 1.4) objective with 2 times averaging. Excitation was at 543 nm and emission collected through a 585-nm long-pass filter. Western analysis Following culture, 106 cells were rapidly lysed in boiling, reducing sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer containing aprotinin (20 µg/mL), leupeptin (20 µg/mL), pepstatin (10 µg/mL), and PMSF (400 µg/mL): samples were immediately boiled for 5 minutes with occasional vortexing, and stored at –80°C until use. SDS-PAGE and electrotransfer to PVDF membranes were performed as described.25 Primary antibodies used were anti–Mcl-1; anti–caspase-3, -8, -9, -10; and anti-GAPDH. Horseradish peroxidase–conjugated secondary antisera used were donkey antirabbit IgG and goat antimouse IgG. Bound antibodies were detected using the ECL system. Densitometry on carefully exposed blots (to avoid film saturation) was performed with Image 1.44 VDM software (National Institutes of Health, Bethesda, MD). Ponceau S–stained actin on membranes after electrotransfer and levels of GAPDH were measured to confirm equivalence of loading of neutrophil samples. MCL-1 and BFL-1: luciferase reporter gene assay The human MCL-1 promoter cloned into the pGL3-Basic luciferase reporter system was used to measure rates of MCL-1 transcription, as described previously.26 The human BFL-1 promoter (a kind gift from Dr D. Walls, School of Biotechnology, Dublin City University) cloned into pGL2-Basic luciferase reporter system was used to measure BFL-1 transcription.27 In addition, 1 µg pRL-SV40 (luciferase driven by SV40 early enhancer/promoter) was added to each transfection as an internal control. HeLa cells were seeded at 2 x 105 cells/2 mL in 35-mm culture dishes and allowed to adhere overnight. Cells were then transfected using Fugene 6 (Welwyn Garden City, United Kingdom) in a 2:1 ratio (2 µL:1 µg DNA) and incubated overnight. After transfection, cells were incubated for 30 minutes at 37°C in the presence or absence of the NF-B inhibitor parthenolide (10 µM) before 24-hour incubation with the indicated stimulants (GM-CSF [50 U/mL], phorbol ester [10 nM] or TNF [10 ng/mL]), at 37°C in a humidified incubator with 5% CO2. Growth media were removed and the cells washed with PBS (lacking Mg2+/Ca2+) before lysis of cells with buffer supplied in the kit. Luciferase activity was assayed (as described in the manufacturer's instructions). Transfected cells were harvested after 24-hour incubation and cells were lysed in 100 µL passive lysis buffer provided with the kit; cell debris was pelleted by centrifugation. Cell lysate (20 µL) was used for each luciferase assay using a Berthold Lumistar luminometer (BMG, Offenburg, Germany). Peak values (which are proportional to luciferase concentration) were recorded. Transfection efficiencies were normalized to Renilla luciferase activity. All values were converted to fold luciferase activities by comparison with the activity measured of the control plasmid (pGL-3 Basic). All experiments were performed in triplicate and data shown represent mean values with error bars showing standard deviations. Quantitative real-time PCR assay Neutrophils were left untreated or treated with 10 ng/mL TNF for the indicated period after which they were lysed and total RNA was extracted using TRIzol before cleaning with RNeasy mini kit. cDNA was synthesized using AMW reverse transcriptase. Quantitative real-time PCR analysis was carried out on the Corbett Rotorgene RG3000 Detection System using the Quantitect SYBR Green PCR kit as recommended by the manufacturer (Corbett Research, Sydney, Australia). Each sample was tested in triplicate and cDNA species were amplified using real-time quantitative reverse-transcription (qRT)–PCR, and this was carried out to measure the relative levels of MCL-1, BAX, and BFL-1 gene expression using the comparative cycle threshold (Ct). The values for β-actin were used to normalize the gene expression data. The relative value of target gene expression was calculated from the standardized target gene and β-actin amplified curves. The cycling conditions were 95°C/15 minutes with a melt of 95°C/15 seconds on first cycle and 40 cycles of 95°C/6 seconds, 60°C/25 seconds, and 72°C/1 minute. The cycle threshold was determined to provide the optimal standard curve values (0.98 to 1.0). Specific primers were Mcl-1 (forward, 5'-GGGCAGGATTGTGACTCTCATT-3'; reverse 5'-GATGCAGCTTTCTTGGTTTATGG-3'); Bax (forward, 5'-CCCACCAGCTCTGAGCAGATC-3'; reverse, 5'-CAGTTGAAGTTGCCGTCAGAA-3'); Bfl-1 (forward, 5'-CGGCATCATTAACTGGGGAAG-3'; reverse, 5'-TGGTCAACAGTATTGCTTCAGGA-3'), and β-actin (forward, 5'-AAGGATTCCTATGTGGGCGAC-3'; reverse, 5'-CGCGGTTGGCCTTGGGGTTCA-3'). Microarray analysis Atlas nylon arrays for apoptosis genes were used to analyze RNA samples of neutrophils incubated for 3 hours in the presence and absence of TNF (10 ng/mL). Gene expression analysis was performed pairwise using control neutrophil samples versus TNF-stimulated neutrophils. RNA isolation and reverse transcription were performed as previously described; labeling (33P-ATP) and hybridization were performed per the manufacturer's instructions. Nylon arrays were exposed to GP/LE phosphor screens (Molecular Dynamics, Sunnyvale, CA) for 24 hours, and scanned using a Storm PhosphorImager (Molecular Dynamics). IMAGEQUANT (Molecular Dynamics) or ATLASIMAGE 2.01 (Clontech) was used for quantitation of signal intensities. Statistics Datasets were analyzed using the Student t test.    Results Top Abstract Introduction Methods Results Discussion Authorship References   Effects of TNF on neutrophil apoptosis and Mcl-1 levels Figure 1A shows that when used at a concentration of 10 ng/mL, TNF enhanced neutrophil apoptosis, compared with control suspensions, as assessed by morphology at 6 hours. However, after 20-hour incubation with TNF, apoptosis was significantly less than that observed in untreated control suspensions, demonstrating the dual effects of this cytokine on neutrophil apoptosis: rapid induction of apoptosis in a subset of cells, but delayed apoptosis in those cells that survive this initial death signal. Figure 1A also shows rates of neutrophil apoptosis when incubated in the presence of GM-CSF (which significantly delays apoptosis) or the protein synthesis inhibitor cycloheximide (which significantly accelerates apoptosis). Similar results were obtained when apoptosis was determined by measuring the binding of FITC–annexin V (Figure 1B). Confocal microscopy of mitochondrial membrane potential (MitoTracker red staining) revealed that these kinetics of apoptosis observed in the population of neutrophils to TNF reflected considerable cell:cell heterogeneity in response to this cytokine (Figure 1C). As control neutrophils aged in culture, their mitochondrial membrane potential gradually decreased (designated as "dim" in Figure 1C), presumably as they lost function and became committed to apoptosis. When 10 ng/mL TNF was added to neutrophils, cells responded in 1 of 2 contrasting ways. First, a subpopulation of cells showed accelerated loss of membrane population such that the "dim" population was significantly greater than that of controls (TNF: 33% ± 5%; control: 5% ± 2%, P < .01). Second, a subpopulation of neutrophils exhibited significantly enhanced mitochondrial membrane potential in response to TNF ("bright" in Figure 1C), which presumably delays their apoptosis. This heterogeneous response to TNF and kinetics of changes in mitochondrial membrane potential is illustrated in Figure 1D, which shows the time course of changes in average fluorescence intensities of 6 cells that lose their mitochondrial membrane potential (and become committed to apoptosis) and 6 cells that undergo a transient enhancement of mitochondrial membrane potential, which then slowly declines. View larger version (39K): [in this window] [in a new window]   Figure 1. Effects of TNF on neutrophil apoptosis. (A) Neutrophils were incubated for 6 hours () or 20 hours () in the absence and presence of GM-CSF (50 U/mL), TNF (10 ng/mL), or CHX (10 µg/mL), prior to measurement of apoptosis by assessment of morphology. There was a significant difference (*P < .05) between apoptosis of controls and TNF-treated neutrophils showing initial increase in neutrophil apoptosis, whereas at 20 hours it acted as a survival factor. Values shown are means (± SD, n = 5). (B) Neutrophils were incubated for either 2 hours or 18 hours as indicated, and apoptosis was determined by measuring the binding of FITC–annexin V and flow cytometry. Values shown are means (± SD, n = 4) and * shows a P value of less than .015 between 2-hour control and 2-hour plus TNF. (C) Neutrophils were stained with MitoTracker red after culture for 2 hours in the absence (control, ) or presence (10 ng/mL, ) of TNF. Graph shows percentage of cells that had either lost (negative) or had decreased (dim) or enhanced (bright) fluorescence, compared with that measured in the cell population at time zero. Insert shows representative confocal images. Values shown are means (± SD, n = 5). (D) Mean fluorescence of 6 individual cells whose fluorescence either decreased or was enhanced following TNF (10 ng/mL) treatment, together with representative confocal images of MitoTracker red fluorescence.   These changes in rates of apoptosis were associated with changes in the levels of Mcl-1, a key regulator of apoptosis in neutrophils.2–6 Figure 2A shows that levels of this antiapoptotic protein declined as neutrophils underwent apoptosis. In line with previous reports, GM-CSF partly prevented this decline, whereas cycloheximide accelerated the loss of this protective protein.8 These observations are explained by the facts that (1) in the presence of cycloheximide to block protein synthesis, the protein undergoes rapid, constitutive turnover and (2) GM-CSF increases cellular levels by delaying this turnover.8 TNF treatment of neutrophils resulted in decreased levels of Mcl-1, compared with control levels, but remarkably, Mcl-1 was barely detectable in cells treated with both TNF and cycloheximide. These results would indicate that TNF treatment accelerates the rate of turnover of Mcl-1 above the rate of constitutive turnover, a result that was confirmed in Figure 2B. In these experiments, the half-life of Mcl-1 in control cells (time required for a 50% decrease in the levels of protein remaining in cycloheximide-treated cells) was just more than 3 hours, while in the presence of TNF this half-life was decreased to approximately 1.5 hours. View larger version (29K): [in this window] [in a new window]   Figure 2. Changes in Mcl-1 protein stability induced by TNF. (A) Neutrophils were incubated in the presence of the protein synthesis inhibitor cycloheximide (CHX) at 10 µg/mL, in the presence or absence of TNF (10 ng/mL) or GM-CSF (50 U/mL). Protein lysates were prepared after 2-hour () and 5-hour () incubation, and Mcl-1 levels were detected by Western blotting. Top panel shows a representative blot of Mcl-1 protein and GAPDH protein as a loading control (after 5-hour incubation), while the bottom panel shows mean data (± SD) of relative Mcl-1 levels (taking the signal at time zero as 100%) of 3 separate experiments. (B) Neutrophils were incubated in the presence of cycloheximide alone or with TNF, and at 1-hour intervals, protein lysates were prepared for analysis of Mcl-1 levels by Western blotting. Inset shows representative Western blots (plus GAPDH levels as loading control), while graph shows mean values of repeat experiments (± SD, n = 5).   Regulation of TNF–induced Mcl-1 turnover These changes in Mcl-1 levels in the presence of cycloheximide were paralleled by changes in the rate of neutrophil apoptosis. After 3-hour incubation with cycloheximide, neutrophil apoptosis was approximately 50% of the cell population, but this apoptosis was significantly blocked by the addition of the proteasome inhibitor, MG-132 (Figure 3A). The addition of GM-CSF to cycloheximide-treated cells slowed the rate of apoptosis, and again, the proteasomal inhibitor blocked this apoptosis, in line with preventing Mcl-1 turnover. In contrast, the pan-caspase inhibitor, Z-VAD, had no significant effect on control- or GM-CSF–regulated apoptosis under these conditions. In line with its ability to greatly enhance the rate of Mcl-1 turnover, TNF treatment resulted in 100% apoptosis of cycloheximide-treated cells by 3-hour incubation (Figure 3A). However, in complete contrast to constitutive and GM-CSF–regulated apoptosis, the proteasomal inhibitor had no effect on TNF-enhanced apoptosis, but instead the pan-caspase inhibitor, Z-VAD, blocked apoptosis. These results would suggest that TNF triggers a new pathway of caspase-dependent apoptosis. View larger version (57K): [in this window] [in a new window]   Figure 3. Role of caspases in TNF-induced apoptosis and Mcl-1 turnover. (A) Neutrophils were incubated in the presence of cycloheximide (10 µg/mL) alone, or with TNF (10 ng/mL) or GM-CSF (50 U/mL) in the absence () or presence of either MG132 (50 µM, ) or Z-VAD-FMK (Cas In 50 µM, ). After 3-hour incubation, samples were removed and apoptosis was determined by morphology. Side panel shows representative cytospins. Typical result of 3 separate experiments. (B) Neutrophils were incubated as described for panel A but after 2 hours and 5 hours, protein lysates were analyzed by Western blotting for levels of Mcl-1 or GAPDH. Typical result of 3 separate experiments.   TNF–mediated caspase activation It was then necessary to determine whether TNF accelerated Mcl-1 turnover via caspase-dependent processes. Neutrophils were incubated for 2 and 5 hours with cycloheximide in the presence and absence of GM-CSF or TNF, together with the proteasomal inhibitor MG-132 or the pan-caspase inhibitor, Z-VAD. Figure 3B shows that both constitutive and GM-CSF–delayed turnover of Mcl-1 were partly blocked by the proteasomal inhibitor, but the pan-caspase inhibitor did not protect against degradation under these conditions. In contrast, TNF-accelerated Mcl-1 turnover was largely proteasome independent but caspase dependent. We then confirmed that TNF triggers caspase activation in neutrophils by measuring levels of either procaspases or activated (cleaved) caspases in Western blots following treatment. As can be seen in Figure 4, TNF resulted in greatly increased levels of activation of a number of caspases, shown as decreased levels of procaspases-3, -8, -9, and -10 and increased levels of cleaved (active) caspases-3 and -8. Note that we could not detect any cleaved (active) caspase-9, presumably because the activated enzyme is unstable and our anti–caspase-10 antibody detected only pro–caspase-10. The pan-caspase inhibitor, Z-VAD (but not MG-132), could prevent activation of these caspases following TNF treatment. View larger version (70K): [in this window] [in a new window]   Figure 4. Activation of caspases by TNF. Neutrophils were incubated in the presence of cycloheximide (10 µg/mL), alone (control), or with TNF (10 ng/mL) or GM-CSF (50 U/mL) in the presence or absence MG132 (50 µM) and Z-VAD-FMK (50 µM). After 5-hour incubation, samples were removed and levels of caspases-3, -8, -9, and -10 (or GAPDH as a loading control) were detected by Western blotting. Typical result of 3 separate experiments.   These experiments conclusively show that the accelerated rate of neutrophil apoptosis induced by TNF results from activation of caspase-dependent turnover of Mcl-1. However, these data do not explain the protective effect of TNF on the subpopulation of cells that survive this initial, rapid induction of cell death. Clearly, other survival mechanisms must operate. Effects of TNF on neutrophil gene expression We therefore measured global changes in expression of cell death and survival genes induced by TNF using a macroarray. TNF induced only small changes in expression of only a small number of genes of interest, examples of which are shown in Figure 5A. For example, TNF treatment did not alter the levels of mRNA for caspase-3 or Mcl-1, but significantly increased levels of mRNA for BFL-1, an antiapoptotic protein that has been implicated previously in neutrophil survival. These results were confirmed in a luciferase reporter gene assay (Figure 5B). Whereas MCL-1 transcription was enhanced by GM-CSF and the phorbol ester, PMA, TNF had no effect on MCL-1 transcription. Furthermore, neither constitutive nor activated transcription of MCL-1 appeared to involve NF-B, as the inhibitor parthenolide had no effect on reporter gene activity. In contrast, TNF (and PMA) stimulated the transcription of BFL-1 via an NF-B–dependent pathway, whereas GM-CSF had no effect on transcription of this gene. These results were confirmed by real-time RT-PCR, showing that BFL-1 mRNA, but not BAX or MCL-1 mRNA, was enhanced by treatment of neutrophils with TNF (Figure 5C). View larger version (23K): [in this window] [in a new window]   Figure 5. Effects of TNF on mRNA levels. (A) mRNA samples of freshly isolated neutrophils and neutrophils incubated in the presence of TNF (10 ng/mL) for 3 hours were determined using Atlas nylon arrays. Selected spots shown are those of caspase-3, MCL-1, and BFL-1. Typical result of 1 of 3 separate experiments using neutrophils from different donors. (B) HeLa cells were transfected with luciferase vectors driven by either the BFL-1 or MCL-1 promoters. Twenty-four hours after transfection, the cells were incubated in the presence or absence of GM-CSF (50 U/mL), TNF (10 ng/mL), or PMA (10 µg/mL) with () or without () the NF-B inhibitor parthenolide (10 µM). Values shown are means (± SD, n = 3). (C) Neutrophils were incubated in the presence of TNF (10 ng/mL), and RNA samples were isolated at the indicated time points. Levels of transcripts for BAX (), BFL-1 (), and MCL-1 () mRNA were measured using quantitative real-time PCR (normalized to GAPDH levels). Values shown are means (± SD, n = 3).   Previous work has reported that the differential effects of TNF on neutrophil apoptosis are concentration dependent,18 low concentrations having antiapoptotic effects but higher concentrations stimulating cell death. We then determined if the differential effects of TNF that we observed on neutrophil Mcl-1 turnover and BFL-1 expression were concentration dependent. Figure 6A shows that the accelerated turnover of Mcl-1 occurred only at concentrations of TNF of 10 ng/mL and higher, while maximal increases in BFL-1 transcription occurred at TNF concentrations of 0.1 and 1 ng/mL (Figure 6B). View larger version (32K): [in this window] [in a new window]   Figure 6. Effects of TNF on relative levels of Bfl-1 and Mcl-1. Neutrophils were incubated in the presence or absence of the indicated concentrations of TNF, or cycloheximide (CHX, 10 µg/mL) for 3 hours. (A) Protein lysates were prepared and Mcl-1 levels were detected by Western blotting. A representative blot of Mcl-1 protein levels from 3 separate experiments is shown. (B) RNA samples were processed and quantitative real-time PCR was performed. Values shown are means (± SD, n = 3)      Discussion Top Abstract Introduction Methods Results Discussion Authorship References   TNF exerts numerous effects on a variety of cell types, varying dramatically from inducing cell death in some cells but conversely promoting cell survival in others. These pleiotropic effects may involve its interaction with different receptors (TNFR55 and TNFR75) and how these are coupled to intracellular signaling pathways that regulate cell function.28 Neutrophils appear somewhat unusual in that TNF can exert these opposing effects on death or cell survival on subpopulations of cells in what appears to be a concentration-dependent process.17,18 In this report, we show, for the first time, that these opposing effects on neutrophil apoptosis are due to differential effects on elements of the antiapoptotic machinery of these cells. We propose that cell death (at concentrations of 10 ng/mL and higher) occurs by rapid, caspase-dependent turnover of the antiapoptotic protein Mcl-1, whereas cell survival occurs via TNF-mediated activation of Bfl-1 expression, another antiapoptotic survival mechanism. Notably, when de novo synthesis is blocked (by cycloheximide), 100% of the cells become apoptotic within 2 hours of TNF treatment. This clearly demonstrates that active gene expression is required to maintain neutrophil survival following TNF treatment. In addition, the data presented here show, for the first time, that the population of blood neutrophils contains subpopulations of cells that differ markedly in their responsiveness to a single concentration of TNF: at a concentration of 10 ng/mL, a subpopulation of neutrophils undergoes rapid loss of mitochondrial membrane potential (and becomes committed to apoptosis), whereas another subpopulation displays enhanced mitochondrial membrane potential that is beneficial to apoptosis delay. The reason for this altered responsiveness is unknown, but it could represent cells in the blood of different ages following their release from the bone marrow, or functional heterogeneity based upon, for example, altered expression of death receptors or altered levels of proapoptotic or antiapoptotic proteins in individual cells. There is now much evidence demonstrating the central role of Mcl-1 in regulating neutrophil survival.2–5 This is an unusual antiapoptotic member of the Bcl-2 family, with some unique properties that distinguish it from other family members. Mcl-1 has a large N-terminal domain, not present in other family members, that confers many of its specialized properties.29 Motifs within this N-terminal domain are targets for posttranslational modifications and give the molecule the unique ability to be acutely up- or down-regulated within minutes of the cell receiving a particular stimulus. This region of the protein also contains a number of PEST domains, and the protein is ubiquitinated by its own E3 ligase (MULE) that targets the protein for proteasomal degradation.30 Indeed, proteasomal inhibition can prevent Mcl-1 turnover, and hence such treatment delays both constitutive and GM-CSF–delayed neutrophil apoptosis. The domain also contains 2 caspase-cleavage sites,31 and caspase-dependent cleavage of Mcl-1 is seen after triggering of apoptosis by agents such as bisindolmaleimide and sodium salicylate.10,32 Also present in this region are a number of potential phosphorylation sites. Some of these remain undefined, but phosphorylation of Thr163 stabilizes the protein, while phosphorylation of Ser159 destabilizes the protein and accelerates its rate of turnover.9,33 Kinases such as Raf, Ras, PI3K, Akt, ERK, and GSK are responsible for these modifications that alter the rate of Mcl-1 turnover and hence its ability to protect against apoptosis. We show here that TNF-induced degradation of Mcl-1 occurs via caspase-dependent processes as shown by the fact that the pan-caspase inhibitor Z-VAD blocks TNF-induced turnover and protects against apoptosis. Furthermore, TNF induced activation of caspases-3, -8, -9, and -10; this activation itself was prevented by Z-VAD. Previous reports have suggested caspase-independent mechanisms of TNF induced neutrophil death,34–36 based on the fact that Z-VAD may actually enhance TNF-induced apoptosis. However, these effects of Z-VAD are strictly concentration dependent.37 The concentrations used in our studies clearly block TNF-stimulated, caspase-mediated neutrophil apoptosis, and much higher concentrations are required to observe these unusual effects of Z-VAD. Once we had shown that TNF-induced neutrophil apoptosis results from the acceleration of Mcl-1 turnover, we then set out to understand the mechanism of TNF-induced survival. Neutrophils are unusual in that they are devoid of the more widely expressed antiapoptotic molecules, Bcl-2 and Bcl-XL.5 These latter proteins are relatively stable within cells and hence not as suited to switching activity (by changes in turnover rate) as Mcl-1. This may explain why neutrophils express Mcl-1 rather than Bcl-2 and Bcl-XL: rapid changes in Mcl-1 function via posttranslational modification permit neutrophils to switch cell fate very rapidly from survival to death in response to external signals. We then sought to identify neutrophil genes whose expression was activated by TNF, using a macroarray. To our surprise, very few genes involved in cell death and survival were regulated by TNF in neutrophils. TNF did not alter mRNA levels for Mcl-1 or a range of death proteins, but did stimulate a significant increase in mRNA for another antiapoptotic molecule, Bfl-1. It is well established that Bfl-1 expression is TNF regulated via an NF-B–dependent process and can protect against apoptosis.38–40 Enhanced Bfl-1 expression has been reported previously in cytokine-treated neutrophils,41 but we clearly show here that Bfl-1 and Mcl-1 expression is independently regulated, strongly suggesting that these 2 antiapoptotic systems may function cooperatively to protect against neutrophil apoptosis, in response to different signaling pathways. However, unlike studies using murine cells,42 defining the role of Bfl-1 in human neutrophils continues to be frustrated by the lack of a specific antibody that can unambiguously identify the protein in Western blots. In summary, we show that the proapoptotic effects of TNF on human neutrophils result from stimulation of a caspase-dependent process of accelerated Mcl-1 turnover. However, TNF can also trigger expression of the antiapoptotic Bfl-1. These effects of TNF are very much concentration dependent: higher concentrations stimulating Mcl-1 degradation, and lower concentrations triggering Bfl-1 expression. These concentration-dependent effects will have profound implications on how TNF may regulate neutrophil function in vivo and hence how anti-TNF therapy may affect immune function.43 At concentrations of TNF of 1 ng/mL or less, the major effect is antiapoptotic and so blocking its function in disease is predicted to accelerate neutrophil apoptosis and thereby help resolve inflammation.    Authorship Top Abstract Introduction Methods Results Discussion Authorship References   Contribution: S.W.E. designed the study, analyzed data, and wrote the paper; A.C. performed experiments and analyzed data; and R.J.M. analyzed data and wrote paper. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Steven W. Edwards, Biosciences Building, Crown Street, University of Liverpool, Liverpool L69 7ZB, United Kingdom; e-mail: s.w.edwards{at}liv.ac.uk.    Acknowledgments   We thank the North West Cancer Research Fund, Aintree Arthritis Research Trust, and Wyeth for financial support.    Footnotes   Submitted May 30, 2007; accepted September 9, 2007. Prepublished online as Blood First Edition Paper, October 17, 2007 DOI: 10.1182/blood-2007-05-087833 The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Methods Results Discussion Authorship References   Akgul C, Moulding DA, Edwards SW. Molecular control of neutrophil apoptosis. FEBS Lett 2001; 487:318–322.[CrossRef][Medline] [Order article via Infotrieve] Cross A, Barnes T, Bucknall RC, Edwards SW, Moots RJ. Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints. J Leukoc Biol 2006; 80:521–528.[Abstract/Free Full Text] Moulding DA, Quayle JA, Hart CA, Edwards SW. Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood 1998; 92:2495–2502.[Abstract/Free Full Text] Edwards SW, Derouet M, Howse M, Moots RJ. Regulation of neutrophil apoptosis by Mcl-1. Biochem Soc Trans 2004; 32:489–492.[CrossRef][Medline] [Order article via Infotrieve] Moulding DA, Akgul C, Derouet M, White MR, Edwards SW. BCL-2 family expression in human neutrophils during delayed and accelerated apoptosis. J Leukoc Biol 2001; 70:783–792.[Abstract/Free Full Text] Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 1995; 128:1173–1184.[Abstract/Free Full Text] Yoon JH, Werneburg NW, Higuchi H, et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002; 62:6500–6505.[Abstract/Free Full Text] Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem 2004; 279:26915–26921.[Abstract/Free Full Text] Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006; 21:749–760.[CrossRef][Medline] [Order article via Infotrieve] Derouet M, Thomas L, Moulding DA, et al. Sodium salicylate promotes neutrophil apoptosis by stimulating caspase-dependent turnover of Mcl-1. J Immunol 2006; 176:957–965.[Abstract/Free Full Text] Mpofu S, Fatima F, Moots RJ. Anti-TNF-a therapies: they are all the same (aren't they?). Rheumatology 2004; 44:271–273.[CrossRef][Medline] [Order article via Infotrieve] Van Assche D. Emerging drugs to treat Crohn's Disease. Expert Opin Emerg Drugs 2007; 12:49–59.[CrossRef][Medline] [Order article via Infotrieve] Suzuki K, Hino M, Hato F, Tatsumi N, Kitagawa S. Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-. Blood 1999; 93:341–349.[Abstract/Free Full Text] Gon S, Gatanaga T, Sendo F. Involvement of two types of TNF receptor in TNF- induced neutrophil apoptosis. Microbiol Immunol 1996; 40:463–465.[Medline] [Order article via Infotrieve] Kilpatrick LE, Lee JY, Haines KM, Campbell DE, Sullivan KE, Korchak HM. A role for PKC-delta and PI 3-kinase in TNF--mediated antiapoptotic signaling in the human neutrophil. Am J Physiol Cell Physiol 2002; 283:C48–C57.[Abstract/Free Full Text] Salamone G, Giordano M, Trevani AS, et al. Promotion of neutrophil apoptosis by TNF-. J Immunol 2001; 166:3476–3483.[Abstract/Free Full Text] Murray J, Barbara JA, Dunkley SA, et al. Regulation of neutrophil apoptosis by tumor necrosis factor-: requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. Blood 1997; 90:2772–2783.[Abstract/Free Full Text] van den Berg JM, Weyer S, Weening JJ, Roos D, Kuijpers TW. Divergent effects of tumor necrosis factor on apoptosis of human neutrophils. J Leukoc Biol 2001; 69:467–473.[Abstract/Free Full Text] Watson F, Robinson J, Edwards SW. Protein kinase C-dependent and -independent activation of the NADPH oxidase of human neutrophils. J Biol Chem 1991; 266:7432–7439.[Abstract/Free Full Text] Robinson J, Watson F, Bucknall RC, Edwards SW. Activation of neutrophil reactive-oxidant production by synovial fluid from patients with inflammatory joint disease: soluble and insoluble immunoglobulin aggregates activate different pathways in primed and unprimed cells. Biochem J 1992; 286:345–351.[Medline] [Order article via Infotrieve] Moulding DA, Walter C, Hart CA, Edwards SW. Effects of staphylococcal enterotoxins on human neutrophil functions and apoptosis. Infect Immun 1999; 67:2312–2318.[Abstract/Free Full Text] Edwards SW, Holden CS, Humphreys JM, Hart CA. Granulocyte-macrophage colony-stimulating factor (GM-CSF) primes the respiratory burst and stimulates protein biosynthesis in human neutrophils. FEBS Lett 1989; 256:62–66.[CrossRef][Medline] [Order article via Infotrieve] Watson F, Robinson JJ, Phelan M, Bucknall RC, Edwards SW. Receptor expression in synovial fluid neutrophils from patients with rheumatoid arthritis. Ann Rheum Dis 1993; 52:354–359.[Abstract/Free Full Text] Savill J. Macrophage recognition of senescent neutrophils. Clin Sci 1992; 83:649–655.[Medline] [Order article via Infotrieve] Moulding DA, Hart CA, Edwards SW. Regulation of neutrophil FcRIIIb (CD16) surface expression following delayed apoptosis in response to GM-CSF and sodium butyrate. J Leukoc Biol 1999; 65:875–882.[Abstract] Akgul C, Turner PC, White MR, Edwards SW. Functional analysis of the human MCL-1 gene. Cell Mol Life Sci 2000; 57:684–691.[CrossRef][Medline] [Order article via Infotrieve] D'Souza BN, Edelstein LC, Pegman PM, et al. Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J Virol 2004; 78:1800–1816.[Abstract/Free Full Text] Renshaw SA, Parmar JS, Singleton V, et al. Regulation of neutrophil apoptosis by tumor necrosis factor-: requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. Blood 1997; 90:2772–2783.[Abstract/Free Full Text] Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 1993; 90:3516–3520.[Abstract/Free Full Text] Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121:1085–1095.[CrossRef][Medline] [Order article via Infotrieve] Clohessy JG, Zhuang J, Brady HJ. Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. Br J Haematol 2004; 125:655–665.[CrossRef][Medline] [Order article via Infotrieve] Snowden RT, Sun XM, Dyer MJ, Cohen GM. Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1. Leukemia 2003; 17:1981–1989.[CrossRef][Medline] [Order article via Infotrieve] Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004; 23:5301–5315.[CrossRef][Medline] [Order article via Infotrieve] Maianski NA, Roos D, Kuijpers TW. Tumor necrosis factor induces a caspase-independent death pathway in human neutrophils. Blood 2003; 101:1987–1995.[Abstract/Free Full Text] Liu CY, Takemasa A, Liles WC, et al. Broad-spectrum caspase inhibition paradoxically augments cell death in TNF--stimulated neutrophils. Blood 2003; 101:295–304.[Abstract/Free Full Text] Chen HC, Wang CJ, Chou CL, et al. Tumor necrosis factor- induces caspase-independent cell death in human neutrophils via reactive oxidants and associated with calpain activity. J Biomed Sci 2006; 13:261–273.[CrossRef][Medline] [Order article via Infotrieve] Cowburn AS, White JF, Deighton J, Walmsley SR, Chilvers ER. z-VAD-fmk augmentation of TNF-stimulated neutrophil apoptosis is compound specific and does not involve the generation of reactive oxygen species. Blood 2005; 105:2970–2972.[Abstract/Free Full Text] Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNF-induced apoptosis. Genes Dev 1999; 13:382–387.[Abstract/Free Full Text] Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-B induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923–5929.[Abstract/Free Full Text] Duriez PJ, Wong F, Dorovini-Zis K, Shahidi R, Karsan A. A1 functions at the mitochondria to delay endothelial apoptosis in response to tumor necrosis factor. J Biol Chem 2000; 275:18099–18107.[Abstract/Free Full Text] Chuang PI, Yee E, Karsan A, Winn RK, Harlan JM. A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem Biophys Res Commun 1998; 249:361–365.[CrossRef][Medline] [Order article via Infotrieve] Orlofsky A, Somogyi RD, Weiss LM, Prystowsky MB. The murine antiapoptotic protein A1 is induced in inflammatory macrophages and constitutively expressed in neutrophils. J Immunol 1999; 163:412–419.[Abstract/Free Full Text] Capsoni F, Sarzi-Puttini P, Atzeni F, et al. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res Ther 2005; 7:R250–R255.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Paunel-Gorgulu, M. Zornig, T. Logters, J. Altrichter, U. Rabenhorst, J. Cinatl, J. Windolf, and M. Scholz Mcl-1-Mediated Impairment of the Intrinsic Apoptosis Pathway in Circulating Neutrophils from Critically Ill Patients Can Be Overcome by Fas Stimulation J. Immunol., November 15, 2009; 183(10): 6198 - 6206. [Abstract] [Full Text] [PDF] S. Moriceau, C. Kantari, J. Mocek, N. Davezac, J. Gabillet, I. C. Guerrera, F. Brouillard, D. Tondelier, I. Sermet-Gaudelus, C. Danel, et al. Coronin-1 Is Associated with Neutrophil Survival and Is Cleaved during Apoptosis: Potential Implication in Neutrophils from Cystic Fibrosis Patients J. Immunol., June 1, 2009; 182(11): 7254 - 7263. [Abstract] [Full Text] [PDF] D. M. Pritchard, D. Berry, S. M. C. Przemeck, F. Campbell, S. W. Edwards, and A. Varro Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor Am J Physiol Gastrointest Liver Physiol, October 1, 2008; 295(4): G798 - G805. [Abstract] [Full Text] [PDF] M. Hurtado-Nedelec, S. Chollet-Martin, P. Nicaise-Roland, S. Grootenboer-Mignot, R. Ruimy, O. Meyer, and G. Hayem Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome Rheumatology, August 1, 2008; 47(8): 1160 - 1167. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: blood-2007-05-087833v1 111/2/878    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cross, A. Articles by Edwards, S. W. Search for Related Content PubMed PubMed Citation Articles by Cross, A. Articles by Edwards, S. W. Related Collections Phagocytes Apoptosis Gene Expression Social Bookmarking                   What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020